The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABVC | +392.34% | -93.81% | -42.65% | -89% |
| S&P | +13% | +86.41% | +13.26% | +482% |
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.80M | 104.5% |
| Gross Profit | $0.70M | 83.2% |
| Gross Margin | 87.94% | -10.2% |
| Market Cap | $71.57M | 743.0% |
| Market Cap / Employee | $3.77M | 0.0% |
| Employees | 19 | 0.0% |
| Net Income | -$1.29M | -858.9% |
| EBITDA | -$1.07M | -1982.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.85M | 10.9% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.16M | 15.4% |
| Short Term Debt | $2.43M | -6.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.10% | 28.9% |
| Return On Invested Capital | -248.40% | -106.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.14M | -276.1% |
| Operating Free Cash Flow | -$0.13M | -269.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.90 | 1.61 | 6.33 | 8.47 | 752.54% |
| Price to Sales | 16.06 | 31.21 | 98.88 | 88.61 | 432.81% |
| Price to Tangible Book Value | 0.90 | 1.61 | 6.33 | 8.47 | 752.54% |
| Enterprise Value to EBITDA | -64.29 | -35.55 | -19.12 | -69.76 | -139.72% |
| Return on Equity | -97.4% | -27.0% | -39.9% | -40.3% | -55.64% |
| Total Debt | $3.20M | $2.99M | $2.31M | $2.59M | -5.56% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
